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Abstract
Background: The aim of this work is to estimate the French frequencies of dispensed
psychotropic prescriptions in children and adolescents. Prevalence estimations of dispensed
prescriptions are compared to the frequencies of use of psychotropic reported by 17 year-old
adolescents.
Methods: Prescription data is derived from national health insurance databases. Frequencies of
dispensed prescriptions are extrapolated to estimate a range for the 2004 national rates. Self-
report data is derived from the 2003 and 2005 ESCAPAD study, an epidemiological study based on
a questionnaire focused on health and drug consumption.
Results: The prevalence estimation shows that the prevalence of prescription of a psychotropic
medication to young persons between 3 and 18 years is about 2.2%.
In 2005, the self-report study (ESCAPAD) shows that 14.9% of 17 year-old adolescents took
medication for "nerves" or "to sleep" during the previous 12 months. The same study in 2003 also
shows that 62.3% of adolescents aged 17 and 18 reporting psychotropic use, took the medication
for anxiety and 56.8% to sleep. Only 49.7% of these medications are suggested by a doctor.
Conclusion: This study underlines a similar range of prevalence of psychotropic prescriptions in
France to that observed in other European countries. Nevertheless, the proportion of
antipsychotics and benzodiazepines seems to be higher, whereas the proportion of
methylphenidate is lower.
Secondly, a disparity between the prevalence of dispensed prescriptions and the self-report of 
actual use of psychotropics has been highlighted by the ESCAPAD study which shows that these 
treatments are widely used as "self-medication".
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Psychotropic medication in children and adolescents is a
matter of concern in most Western countries. However,
few randomized controlled trials have evaluated pharma-
cological treatments in children and adolescents for psy-
chiatric disorders [1,2]. In addition, the official
indications of most psychotropic drugs for children are
not clear and off-label prescriptions have expanded fast
during the last decade [3-5]. Recently, these problems
have been pinpointed as particularly important for some
drugs, since different countries have issued warnings on
serotonin reuptake inhibitor antidepressants [6-8].
In France, little data concerning the frequency of psycho-
tropic treatments in children and adolescents is available.
In 2002, a study [9] based on medication reimbursement
claims registered in the database of a regional branch of
the main health care insurance reported widespread use of
psychotropic medication by French adolescents. In addi-
tion, several epidemiological studies have raised concerns
about psychotropic consumption in France: legal drug use
in France is among the highest in the world and it was the
highest in the European Union in 1997 [10-12].
Unfortunately, no national study on psychotropic pre-
scriptions has as yet been conducted in children and ado-
lescents in France. The aim of this work is to estimate the
national frequencies of prescription of psychotropic treat-
ment (antidepressants, stimulants, antipsychotics and
benzodiazepines) in children and adolescents. Data is
derived from several national health insurance databases.
Results are compared to responses given by adolescents to
a large national epidemiological study.
Methods
Study settings and design
In France, the national health insurance system comprises
three main agencies: CNAM-TS (Caisse Nationale d'Assur-
ance Maladie) for salaried employees, RSI (Régime Social
des indépendants) for independent and self-employed
workers and MSA (Mutuelle Sociale Agricole) for self-
employed and salaried workers in the agricultural sector.
These three agencies account for 96.6% of the French pop-
ulation (86.2% for CNAM TS, 4.4% for RSI, 6.0% for
MSA) [13].
Children and adolescents under 18 are affiliated to their
parent's insurance funds. All prescriptions issued by a
physician and dispensed by pharmacies are coded and put
into a database that is specific to each agency. In each
insurance fund, each claim is specifically coded, registered
in a computerized database and linked to beneficiary
identity.
In this study, we performed two cross sectional studies
analyzing stimulant, benzodiazepine, anti-psychotic and
antidepressant prescriptions in children and adolescents
under 19: the first was conducted among affiliates of the
RSI in 2004, and the second among affiliates of the
CNAM-TS in the "Franche Comté" region in 2005.
As a second step, data derived from the 2003 and 2005
ESCAPAD study, an epidemiological study based on a
self-completed questionnaire focused on health and con-
sumption of medication, was analysed. This survey is per-
formed regularly (2000, 2001, 2002, 2003 and 2005) on
a representative sample of French adolescents during a
"civil service" day for all French subjects aged 17 and 18.
This day replaces the former mandatory military service
check-up, and concerns both boys and girls. The 2003 and
2005 surveys were used, including respectively samples of
15 710 and 29 393 individuals [14,15].
The present study focuses on five particular items in the
questionnaire:
- Do you usually take medication for a psychological
problem (i.e. at least once per week over the last six
months)?
- Have you taken drugs for nerves or to sleep in the last 12
months? If you have, how many times? once or twice,
between 3 and 5 times, between 6 and 9 times, 10 times
and more.
- Have you taken drugs for nerves or to sleep in the last 30
days? If you have, how many times? once or twice,
between 3 and 5 times, between 6 and 9 times, between
10 and 19 times, between 20 and 29 times, every day.
- Who gave you the last medication you took? A physician,
one of your parents, one of your friends, nobody (I took
it by myself), other situation ?
(This question was asked only in 2003)
For what reason did you take this medication? (several
answers possible): to cure some illness, against stress, to
sleep, to get some stimulation, for a party, because of a
traumatic event, other reason)?
(This question was asked only in 2003)
Data management
Concerning data from the health insurance providers, the
prescriptions were collected using ATC classification. All
prescriptions during a given year with an ATC code begin-
ning with N05A (antipsychotics), N05B (anxiolytics),
N05C (hypnotics), N06A (antidepressants), N06B (psy-Page 2 of 7
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refined and medications were finally categorized in the
following groups: methylphenidate, serotonin specific
reuptake inhibitors (SSRI), benzodiazepines and anti-psy-
chotics. It should be noted that methylphenidate is the
only psychostimulant authorized for children in France.
Statistical methods
A model was designed to estimate frequencies of prescrip-
tions according to age and gender: a "year effect" was cal-
culated for each class of medication. The "year effect" is
the ratio between the 2004 and 2005 "Franche Comté"
RSI prevalence of dispensed prescriptions.
As a second step the ratios of prescriptions according class
of medication were calculated between RSI in the
"Franche Comté" region in 2004 and RSI in France in
2004. These ratios were used to estimate a "geographical
effect" for each class of medication.
Complete data concerning the prescription of a medica-
tion according to class, subject age (in years) and gender
for RSI in 2004 was obtained. Combining these data with
the "year effect" and the "geographical effect", the levels of
consumption according to class of drug, age (in years) and
gender for the CNAM-TS in 2004 was then estimated.
The mathematical model is as follows:
P = frequency of prescription
i0 = Franche - Comté; i1 = France
j0 = 2004; j1 = 2005
We have to calculate the estimation of Pcnam (i1, j0)
Year effect = Prsi (i0, j0)/Prsi (i0, j1)
Geographical effect = Prsi(i1, j0)/Prsi(i0, j0)
Pcnam (i1, j0) = Pcnam (i0, j1) × year effect × geograph-
ical effect
Or
Pcnam (i1, j0) = Pcnam (i0, j1) × Prsi (i1, j0)/Prsi (i0,
j1)
We checked that thedistribution between France and
Franche Comté in terms of age and activity (Table 1) was
similar in order to extrapolate prevalence of prescriptions
from Franche Comté to France [16].
We also compared the overall prescriptions of psycho-
tropics between France and Franche Comté in the 2004
RSI database for children and adolescents (Table 1).
Concerning the MSA insurance system, it was hypothe-
sised that the frequencies of psychotropic prescriptions
fell between the RSI frequencies and the CNAM-TS esti-
mations.
The range of the overall prevalence of psychotropics in
France was estimated using the lowest and the highest
hypothesis of the prevalence of prescriptions in the MSA.
Finally, frequencies of prescriptions according to psycho-
tropic class, age and gender were combined for these three
insurance systems using a weighted mean (according to
Table 1: Distribution of age and activity in France and Franche Comté
Franche Comté
(% of the population)
France
(% of the population)
Age
0-19 25.2 25.1
20-39 25.9 26.5
40-59 27.9 27.8
>60 21 20.7
Working population 47.5 52.5
- Employed 42.6 42.1
- Unemployed 4.9 5.4
Non-working population 52.5 52.5
- Retired 20.8
- Students 7.7 20
- Others 20.8 8.2
Psychotropic prevalence 2.1 2.5
Age: 0-18Page 3 of 7
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persons). Since the MSA, CNAM-TS and RSI cover about
96.6% of the French population, this should provide
fairly acceptable estimates of the level of prescriptions in
France.
Results
Description of the population of the health care insurance 
sample
In France in 2004, 536 606 children and adolescents aged
between 0 and 18 were affiliated to the RSI, 13 533 415 to
the CNAM-TS (259 885 to the CNAM-TS Franche-Comté)
and 944 075 to the MSA [15].
There were 15, 124 052 children and adolescents aged
from 0 to 18 in France in 2004 [16].
Hence our model accounts for about 99,3% of the French
population of this age.
All psychotropics (table 2)
The overall annual prevalence of prescriptions of psycho-
tropic medication to young persons between 0 and 18
years is about 2.2%. This annual rate of prescription rises
from approximately 1.2% to 5% between 5 and 18 years.
From 0 to 12 years, the rate of prescription is higher in
boys. At 13, the rate becomes higher in girls. At 18 the gen-
der ratio is about 2:1.
Methylphenidate (table 3)
The maximum prevalence of prescription of methylpheni-
date is obtained in boys aged 8 years, where it is about
0.65%. It can be noted that the age of the maximum prev-
alence of methylphenidate prescription is older in girls.
The rate of prescription is always lower for girls. Most of
the prescriptions are issued for individuals between the
ages of 7 and 16.
Benzodiazepines (table 4)
The rate of benzodiazepine prescription increases with
age. The frequency of prescription is higher in boys until
the age of 13. From 14 to 18 the rate is higher in girls. The
gender ratio is about 2:1 at the ages of 17 and 18. At the
age of 18, the frequency of prescription reaches approxi-
mately 1.2%.
SSRI (table 5)
The prevalence of SSRI prescription increases with age.
From ages 3 to 13 the frequency of prescription fluctuates
between 0.15% to 0.25% and the rates are similar in boys
and girls. From 14, the rate rises from approximately 0.4%
to 1.4%. The percentage of prescriptions of SSRI reaches
2.2% in young women at 18, which is twice as high as in
young men.
Antipsychotics (table 6)
The prevalence of the prescription of antipsychotics also
increases with age. The frequency of prescriptions is
always higher in boys than in girls.
Self-report data collected by ESCAPAD
In 2005, 14.9% of the adolescents aged 17 years old
reported having taken some form of medication for
"nerves" or to sleep in the preceding 12 months (22.0%
for girls, 8.0 for boys, p < 0.0001), 7.7% had taken this
medication in the preceding 30 days (11.8% for girls vs
3.7% for boys, p < 0.0001) and only 2.2% had taken this
medication at least 10 times in the previous 30 days (3.4%
vs 1.1, p < 0.0001). A significant proportion of this medi-
cation (38%) involved plants or homeopathy.
Table 2: Estimation of the French prevalence of psychotropic use 
in 2004
age Boys (‰) Girls (‰) All (‰)
0-4 [6.4 ; 6.8] [6.2 ; 6.6] [6.3 ; 6.7]
5-9 [14.4 ; 15.3] [12.2 ; 13.0] [13.3 ; 14.2]
10-14 [18.6 ; 19.9] [20.1 ; 21.5] [19.3 ; 20.6]
15-18 [25.7 ; 27.4] [49.3 ; 52.6] [37.8 ; 40.3]
all [18.5 ; 19.7] [24.6 ; 26.2] [21.5 ; 22.9]
Table 3: Estimation of the French prevalence of 
methylphenidate use in 2004
age Boys (‰) Girls (‰) All (‰)
0-4 [0.054 ; 0.055] [0.027 ; 0.028] [0.040 ; 0.041]
5-9 [3.0; 3.1] [5.1 ; 5.2] [1.8 ; 1.9]
10-14 [3.7 ; 3.8] [0.69 ; 0.71] [2.7 ; 2.8]
15-18 [1.7 ; 1.8] [0.27 ; 0.28] [1.0 ; 1.1]
all [2.5 ; 2.6] [0.38 ; 0.39] [1.4 ; 1.5]
Table 4: Estimation of the French prevalence of benzodiazepine 
use in 2004
age Boys (‰) Girls (‰) All (‰)
0-4 [0.070 ; 0.0071] [0.075 ; 0.076] [0.73 ; 0.74]
5-9 [0.47 ; 0.48] [0.50 ; 0.51] [0.48 ; 0.49]
10-14 [1.8 ; 1.9] [1.8 ; 1.9] [1.8 ; 1.9]
15-18 [5.7 ; 5.8] [11.9 ; 12.2] [8.9 ; 9.1]
all [2.1 ; 2.2] [3.9 ; 4.0] [3.0 ; 3.1]
Table 5: Estimation of the French prevalence of SSRI use in 2004
age Boys (‰) Girls (‰) All (‰)
0-4 [1.1 ; 1.2] [1.2 ; 1.3] [1.2 ; 1.3]
5-9 [2.2 ; 2.3] [1.9 ; 2.0] [2.1 ; 2.2]
10-14 [3.0 ; 3.1] [3.5 ; 3.6] [3.3 ; 3.4]
15-18 [8.2 ; 8.4] [15.6; 16.0] [12.0 ; 12.3]
all [4.2 ; 4.4] [6.3 ; 6.5] [5.2 ; 5.4]Page 4 of 7
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they were regularly taking some form of psychotropic
medication (for at least 6 months) for psychological pur-
poses; 3.0% reported that they were being followed by a
physician for a psychological problem at the time of the
survey.
Reasons for the use of psychotropics (table 7)
Results from the 2003 ESCAPAD study show that most of
the psychotropic use that is drugs "for nerves or to sleep"
reported by adolescents aged 17 and 18 years old was for
anxiety or to sleep (it should be noted that the purpose of
use was reported only for the most recent use) while about
10% of use was for fun or stimulation.
Persons who suggested the most recent use of 
psychotropics (table 8)
About half of the psychotropics used by young people at
17 years are taken without a decision by a doctor. This
proportion is negatively correlated with frequency of use:
only 25.0% of adolescents who take some form of psycho-
tropic medication almost daily are concerned.
Discussion
To our knowledge, this is the first national estimation of
psychotropic prescriptions in children and adolescents in
France. Its originality is the comparison of official
national health insurance data with epidemiological data
based on a self-completed questionnaire. These epidemi-
ological statistics provide some interesting information
about the reasons for psychotropic drug use among ado-
lescents.
The main limitation of the study is the restricted access to
the CNAM-TS database (only one region) and the absence
of access to the MSA database. However, we constructed a
model which is liable to deal with this limitation: a range
estimate is provided, which takes into account the absence
of data from the MSA insurance
This calculation of a nationwide estimate highlights sev-
eral trends:
In comparison with other European and North American
countries, the frequency of overall psychotropic prescrip-
tion in France is similar to that in United Kingdom
(approximately 2%), Netherlands (2.9%), and Germany
(2.0%). It is higher than Italy (0.3%) and lower than the
USA (6.7%) [17-27].
A recent study conducted in France in MGEN affiliates
found similar rates of overall psychotropic frequencies of
2.1% vs 2.2% in our study [28]. The frequency of methyl-
phenidate and SSRI prescription is a bit higher in our
study (0,1% for psychostimulants and 0.4% for antide-
pressants in the MGEN study versus 0.15% for methylphe-
nidate and 0.5% for SSRI). For anxiolytics, the
comparison is difficult because the MGEN study takes
herbal medicines into account.
In France, the profile of prescriptions is however different.
Antipsychotics and benzodiazepines seem to be pre-
scribed at a higher level than in many European countries,
whereas methylphenidate appears to be less prescribed. A
hypothesis can be proposed to explain this point: under-
diagnosis of ADHD and the use of symptomatic treat-
ments such as antipsychotics and benzodiazepines to deal
with externalized disorders in children and adolescents.
For methylphenidate prescriptions, the maximum of
prevalence rate is obtained at 8 years for boys and at 10
years for girls. This probably reflects the delay in the diag-
nosis of ADHD between boys and girls.
The ESCAPAD survey is based on a self-completed ques-
tionnaire. Its analysis provides some additional and com-
plementary information. Almost 15% of the adolescents
aged 17 in 2005 took medication "for nerves or to sleep".
If homeopathy and plants are removed, we obtain preva-
lence for consumption of psychotropics of 9% in 17 year-
old adolescents. This percentage is higher than the pre-
scription prevalence derived from the social security data-
bases (4.1-4.4% at the age of 17).
Table 6: Estimation of the French prevalence of antipsychotic 
use in 2004
Boys (‰) Girls (‰) All (‰)
0-4 [0.62 ; 0.64] [0.38 ; 0.39] [0.51 ; 0.52]
5-9 [3.0; 3.1] [1.2; 1.3] [2.1 ; 2.2]
10-14 [4.5 ; 4.6] [1.9 ; 2.0] [3.2 ; 3.3]
15-18 [7.4 ; 7.6] [5.9 ; 6.0] [6.6 ; 6.8]
all [4.1 ; 4.2] [2.5 ; 2.6] [3.3 ; 3.4]
Table 7: Purpose of the most recent psychotropic use among psychotropic users -- ESCAPAD 2003
To cure an illness Against anxiety To sleep To be stimulated For fun After a traumatic event Other
girls 21.2% 71.5% 57.7% 8.5% 1.9% 0.9% 1.4%
boys 28.2% 40.1% 54.5% 9.4% 5.5% 0.4% 1.0%
All 23.3% 62.3% 56.8% 8.8% 3.0% 0.8% 1.3%Page 5 of 7
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tropic drugs without medical prescriptions, or that they
take psychotropic drugs legally obtained with earlier med-
ical prescriptions.
Indeed, in 2003, 49.7% of the adolescents aged 17 who
took some kind of medication for their nerves or to sleep
in previous 12 months reported that they obtained it via a
doctor the last time they took it (table 7); this corresponds
to almost 4.5% of the 17 year-old adolescent population.
This prevalence appears very close to the prevalence noted
in the prescriptions (4.1%).
ESCAPAD also gave some indications about the purpose
of psychotropic medication for adolescents. The main
purpose is different between boys and girls. Girls use psy-
chotropics to deal with anxiety whereas boys use pyscho-
tropics to treat sleep disorders. The use of psychotropics
for stimulation or for fun reaches 10% for girls and
approximately 15% for boys. It would be interesting to
study how this type of use evolves, and which drugs are
the most widely consumed in these indications.
In addition, psychotropics can be used to treat physical
heath problems in children.
We checked all official physical indications for the psy-
chotropics studied and looked for information on non
official indications.
It appears that tricyclic antidepressants are used to treat
enuresis in children and could be marginally use to treat
pain. In this study, only SSRIs were taken into account to
avoid this bias. There are no physical indications found
for this therapeutic class.
Methylphenidate has another official indication which is
narcolepsy. We cannot know the proportion of methyl-
phenidate used to treat narcolepsy. Empirically, it is likely
to be very rare.
Antipsychotics have no official indication to treat physical
health problems in children. Haloperidol is used
although infrequently as an antiemetic drug.
Concerning benzodiazepines, the question is more diffi-
cult. Indeed, benzodiazepines are also indicated to treat
epilepsy in children and in rare instances used as analge-
sic. In our study, it is impossible to know whether benzo-
diazepines are used to treat anxiety or epilepsy. To our
knowledge, in France, there is no publication giving an
estimation of the rates of benzodiazepines used against
anxiety or epilepsy. Empirically, the proportion of benzo-
diazepines used to treat epilepsy is likely to be very low
compared to psychiatric indications. In addition, other
prevalence studies in children do not specify the aim of
the prescription for benzodiazepines. Thus, the preva-
lence estimation in our study can be compared to other
studies.
Conclusion
As a conclusion, this study evidences a similar range of
prevalence of psychotropic prescriptions to young people
in France to that observed in certain European countries,
a higher proportion of antipsychotic and benzodiazepine
use in children and adolescents, and a lower proportion of
methylphenidate use. It suggests an under-diagnosis of
ADHD in France, and probably different approaches to
treating certain psychiatric disorders in children and ado-
lescents.
Secondly, a disparity between dispensed prescriptions and
the self-report of actual use of psychotropics has been
highlighted via data from the ESCAPAD study, showing
that these treatments are widely used as "self-medication".
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